Even if the drug did not have any efficacy data as long as it is...

Even if the drug did not have any efficacy data as long as it is safe ethics would approve it to move forward.

I'm fairly sure this is only an ethics approval not an IND approval. I think they got that already previously? even then IND approvals are not significant.

I would be very interested when we see complete responses or significant durable responses with this cohort. From there, we will be talking about pivotal trial, M&A buyout talks or collaborations, etc.

One important to note IPSC (IPSC CAR-T and CAR-NK cell therapy company) divested on their glioblastoma CAR-T platform so that's something to think about.